News Releases

Highlights the critical role people with diabetes play in their own care and treatment PARSIPPANY, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host an industry-sponsored symposium at the

PARSIPPANY, N.J. , Feb. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three month period ended December 31, 2022 .

PARSIPPANY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (NASDAQ: EMBC) have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of

PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences: 2023 BTIG Medical Technology Conference

PARSIPPANY, N.J., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spinoff from Becton, Dickinson and Company (“BD”), today held a grand opening ceremony at its new global

PARSIPPANY, N.J., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal first quarter 2023 financial results, provide an operational update, and host a question